Trade

Neuland Laboratories share price

High risk
  • 46%Low risk
  • 46%Moderate risk
  • 46%Balanced risk
  • 46%High risk
  • 46%Extreme risk
  • ₹16,055.00(-5.02%)
    December 8, 2025 15:29:18 PM IST
    • NSE
    • BSE
  • Vol : 58.49 K (NSE + BSE)
    Last 20 day avg : 92.60 K

Neuland Laboratories is trading -5.02% lower at Rs 16,055.00 as compared to its last closing price. Neuland Laboratories has been trading in the price range of 16,876.35 & 15,853.65. Neuland Laboratories has given 23.05% in this year & -2.32% in the last 5 days. Neuland Laboratories has TTM P/E ratio 78.03 as compared to the sector P/E of 30.57.There are 4 analysts who have initiated coverage on Neuland Laboratories. There are 2 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 96.85 Crores in its last quarter.Listed peers of Neuland Laboratories include Jagsonpal Pharmaceuticals (-4.87%), Pfizer (-0.37%), Unichem Laboratories (-0.94%).The Mutual Fund holding in Neuland Laboratories was at 9.78% in 30 Sep 2025. The MF holding has increased from the last quarter. The FII holding in Neuland Laboratories was at 20.60% in 30 Sep 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Dec 08, 2025, 02:17 PM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.80
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.10
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.07
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    14.30
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    90.80
    Higher than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    1.52
    Indicates Fair Valuation
Price range
Day Range
Lowest
15,853.65
Highest
16,876.35
52 week range
Lowest
10,060.00
Highest
19,748.40
Neuland Laboratories News
Neuland Laboratories Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Jagsonpal Pharmaceuticals
Bearish
199.20-4.871,329.1636.936.031.153.18
Pfizer
Moderately Bearish
4,977.00-0.3722,792.6135.875.420.701.60
Unichem Laboratories
Bearish
442.95-0.943,104.3923.251.29-3.51
Aurobindo Pharma
Neutral
1,177.60-3.2768,513.3820.342.180.335.52
Astrazeneca Pharma India
Bullish
9,086.70-1.3522,669.99122.7129.870.353.82
Mutual Fund Ownership
View all
LIC MF Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 3.47
  • % of AUM 4.11
ITI Pharma and Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 4.38
  • % of AUM 1.98
PGIM India Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 1.95
  • % of AUM 1.79
Tata Nifty MidSmall Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 2.43
  • % of AUM 1.78
Motilal Oswal Nifty MidSmall Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 0.43
  • % of AUM 1.77
Neuland Laboratories Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2025-11-07Quarterly Results
2025-07-31Quarterly Results
2025-05-15Audited Results & Final Dividend
2025-02-10Quarterly Results
2024-11-06Quarterly Results
About the company Neuland Laboratories
  • IndustryMajor Drugs
  • ISININE794A01010
  • BSE Code524558
  • NSE CodeNEULANDLAB
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
  • Management Info
  • Davuluri RaoExecutive Chairman of the Board
  • Davuluri RaoChief Executive Officer, Whole Time Vice Chairman of the Board
  • Davuluri RaoWhole Time Vice Chairman of the Board, Joint Managing Director
  • Abhijit MajumdarChief Financial Officer
  • Sharadsrikar KotturiChief Scientific Officer
  • Sarada BhamidipatiCompliance Officer, Company Secretary
  • Ashutosh SinhaChief Quality Officer
Neuland Laboratories Share Price FAQs

Neuland Laboratories is trading at 16055.00 as on Mon Dec 08 2025 09:59:18. This is -5.02% lower as compared to its previous closing price of 16903.35.

The market capitalization of Neuland Laboratories is 20617.11 Cr as on Mon Dec 08 2025 09:59:18.

The average broker rating on Neuland Laboratories is Strong Buy. The breakup of analyst rating is given below -

  • 2 analysts have given a strong buy rating
  • 2 analysts have given a buy rating
  • 0.00 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for Neuland Laboratories is 19748.40 whereas the 52 wk low is 10060.00

Neuland Laboratories can be analyzed on the following key metrics -

  • TTM P/E: 78.03
  • Sector P/E: 30.57
  • Dividend Yield: 0.07%
  • D/E ratio: 0.16

Neuland Laboratories reported a net profit of 260.11 Cr in 2025.

The Mutual Fund Shareholding was 9.78% at the end of 30 Sep 2025.

Quick Links
EQUITY QUICK LINKS
Neuland Laboratories QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Business News/Market/Market Stats/  Neuland Laboratories share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.